Citations (117)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Amelia Evoli, Gregorio Spagni, Gabriele Monte & Valentina Damato. (2021) Heterogeneity in myasthenia gravis: considerations for disease management. Expert Review of Clinical Immunology 17:7, pages 761-771.
Read now
Read now
Amelia Evoli, Raffaele Iorio & Emanuela Bartoccioni. (2016) Overcoming challenges in the diagnosis and treatment of myasthenia gravis. Expert Review of Clinical Immunology 12:2, pages 157-168.
Read now
Read now
Shawn Shetty & A. R. Ahmed. (2013) Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 46:8, pages 487-496.
Read now
Read now
Kyung-Ah Park & Sei Yeul Oh. (2013) Current treatment for ocular myasthenia gravis. Expert Review of Ophthalmology 8:6, pages 595-603.
Read now
Read now
Marc H. De Baets. (2010) Insights in the autoimmunity of myasthenia gravis. Autoimmunity 43:5-6, pages 341-343.
Read now
Read now
Alejandro M. Gomez, Joost Van Den Broeck, Kathleen Vrolix, Sofie P. Janssen, Marijke A. M. Lemmens, Eline Van Der Esch, Hans Duimel, Peter Frederik, Peter C. Molenaar, Pilar Martínez-Martínez, Marc H. De Baets & Mario Losen. (2010) Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction. Autoimmunity 43:5-6, pages 353-370.
Read now
Read now
M. Isabel Leite, Patrick Waters & Angela Vincent. (2010) Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 43:5-6, pages 371-379.
Read now
Read now
Articles from other publishers (110)
Xin Chen, Jiayi Qiu, Zihui Gao, Boya Liu, Chen Zhang, Weiran Yu, Jiawen Yang, Yuntian Shen, Lei Qi, Xinlei Yao, Hualin Sun & Xiaoming Yang. (2023) Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies. Biochemical Pharmacology 218, pages 115872.
Crossref
Crossref
Alexion. (2023) Have you diagnosed a patient with NMOSD or gMG?. EMJ Neurology.
Crossref
Crossref
Li Qiu, Pei Chen, Changyi Ou, Juan Deng, Zhidong Huang, Zhongqiang Lin, Qian Ma, Xin Huang, Lu Yu, Hao Ran & Weibin Liu. (2023) Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study. Acta Neurologica Belgica.
Crossref
Crossref
Hruy Menghesha, Michael Schroeter, Christopher Nelke, Tobias Ruck, Georg Schlachtenberger, Clara Welskop, Amina Camo, Matthias Heldwein, Gerardus Bennink, Thorsten Wahlers, Servet Bölükbas, Fabian Doerr & Khosro Hekmat. (2023) The impact of thymectomy in subgroups of Myasthenia gravis patients: a single center longitudinal observation. Neurological Research and Practice 5:1.
Crossref
Crossref
Akiyuki Uzawa, Shigeaki Suzuki, Satoshi Kuwabara, Hiroyuki Akamine, Yosuke Onishi, Manato Yasuda, Yukiko Ozawa, Naoki Kawaguchi, Tomoya Kubota, Masanori P Takahashi, Yasushi Suzuki, Genya Watanabe, Takashi Kimura, Takamichi Sugimoto, Makoto Samukawa, Naoya Minami, Masayuki Masuda, Shingo Konno, Yuriko Nagane & Kimiaki Utsugisawa. (2023) Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. Journal of Neurology, Neurosurgery & Psychiatry 94:6, pages 467-473.
Crossref
Crossref
Rebecca Golfinopoulou, Eleni Papakonstantinou & Dimitrios Vlachakis. (2023) Future perspectives in myasthenia gravis (Review). International Journal of Epigenetics 3:1.
Crossref
Crossref
Debora Brascia, Marco Lucchi, Vittorio Aprile, Melania Guida, Roberta Ricciardi, Federico Rea, Giovanni Maria Comacchio, Marco Schiavon, Maria Carlotta Marino, Stefano Margaritora, Elisa Meacci, Gregorio Spagni, Amelia Evoli, Giulia Lorenzoni, Giulia De Iaco, Angela De Palma & Giuseppe Marulli. (2023) Thymectomy in severe (Myasthenia Gravis Foundation of America classes IV–V) generalized myasthenia gravis: is the game really worth the candle?. European Journal of Cardio-Thoracic Surgery 63:5.
Crossref
Crossref
Shigeaki Suzuki, Masayuki Masuda, Akiyuki Uzawa, Yuriko Nagane, Shingo Konno, Yasushi Suzuki, Tomoya Kubota, Takamichi Sugimoto, Makoto Samukawa, Genya Watanabe, Kei Ishizuchi, Hiroyuki Akamine, Yosuke Onishi, Kazuki Yoshizumi, Takafumi Uchi, Itaru Amino, Yuki Ueta, Naoya Minami, Naoki Kawaguchi, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai & Kimiaki Utsugisawa. (2022)
Japan
MG
registry: Chronological surveys over 10 years
. Clinical and Experimental Neuroimmunology 14:1, pages 5-12.
Crossref
Crossref
Angela Ting, Tyler Story, Coralie Lecomte, Adina Estrin, Sahar Syed & Edward Lee. (2023) A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. Journal of the Neurological Sciences 445, pages 120531.
Crossref
Crossref
Zhe Ruan, Chao Sun, Yanlin Lang, Feng Gao, Rongjing Guo, Quan Xu, Liping Yu, Songdi Wu, Tao Lei, Yu Liu, Min Zhang, Huanhuan Li, Yonglan Tang, Ting Gao, Yanwu Gao, Xiaodan Lu, Zhuyi Li & Ting Chang. (2022) Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis. Frontiers in Immunology 13.
Crossref
Crossref
Marina Mané-Damas, Peter C. Molenaar, Peter Ulrichts, Florit Marcuse, Marc H. De Baets, Pilar Martinez-Martinez & Mario Losen. (2022) Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmunity Reviews 21:7, pages 103104.
Crossref
Crossref
Ying Zhang, Fujun Li, Hongwen Zhu, Hongmei Yu, Tian Wang & Xudong Yan. (2022) Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy. Neurological Sciences 43:6, pages 3949-3956.
Crossref
Crossref
Shengyao Su, Lin Lei, Zhirong Fan, Shu Zhang, Qi Wen, Jingsi Wang, Yan Lu, Li Di, Min Wang, Hai Chen & Yuwei Da. (2022) Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis. Frontiers in Neurology 13.
Crossref
Crossref
Zhuajin Bi, Yayun Cao, Chenchen Liu, Mengcui Gui, Jing Lin, Qing Zhang, Yue Li, Suqiong Ji & Bitao Bu. (2022) Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort. Therapeutic Advances in Chronic Disease 13, pages 204062232211225.
Crossref
Crossref
Yhojan Rodríguez, Lucas Restrepo, Christopher Chang & Juan-Manuel Anaya. 2022. Allergic and Immunologic Diseases. Allergic and Immunologic Diseases
887
975
.
Dubravka Dodig, Angela Genge, Daniel Selchen & Mark S. Freedman. (2021) Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, pages 1-9.
Crossref
Crossref
Yukiko Ozawa, Akiyuki Uzawa, Manato Yasuda, Yuta Kojima, Yosuke Onishi, Fumiko Oda, Tetsuya Kanai, Keiichi Himuro, Naoki Kawaguchi & Satoshi Kuwabara. (2021) Long-term outcomes and prognostic factors in generalized myasthenia gravis. Journal of Neurology 268:10, pages 3781-3788.
Crossref
Crossref
Gyanendra Swaroop Mittal, B. Niranjan Naik & Deepak Sundriyal. (2021) Myasthenia Gravis Following Excision of a Large Thymoma. Indian Journal of Surgical Oncology 12:2, pages 446-449.
Crossref
Crossref
Christian W. Keller, Marc Pawlitzki, Heinz Wiendl & Jan D. Lünemann. (2021) Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis. International Journal of Molecular Sciences 22:11, pages 5755.
Crossref
Crossref
Devin E. Prior, Baillee A. Cooper, Bo Zhang & Partha S. Ghosh. (2021) Developing outcome measures of disease activity in pediatric myasthenia. Muscle & Nerve 63:5, pages 751-757.
Crossref
Crossref
Nakul Katyal, Naureen Narula & Raghav Govindarajan. (2021) Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Journal of Neuromuscular Diseases 8:2, pages 287-294.
Crossref
Crossref
Donald B. Sanders, Shruti M. Raja, Jeffrey T. Guptill, Lisa D. Hobson‐Webb, Vern C. Juel & Janice M. Massey. (2020)
The
D
uke myasthenia gravis clinic registry:
I
.
D
escription and demographics
. Muscle & Nerve 63:2, pages 209-216.
Crossref
Crossref
Agustina M. Lascano & Patrice H. Lalive. (2021) Update in immunosuppressive therapy of myasthenia gravis. Autoimmunity Reviews 20:1, pages 102712.
Crossref
Crossref
Matthew G. Fillingim & Adam J. Woods. 2021. Encyclopedia of Gerontology and Population Aging. Encyclopedia of Gerontology and Population Aging
3452
3459
.
Amelia Evoli & Raffaele Iorio. (2020) Controversies in Ocular Myasthenia Gravis. Frontiers in Neurology 11.
Crossref
Crossref
Richard J. Nowak, Srikanth Muppidi, Said R. Beydoun, Fanny L. O'Brien, Marcus Yountz & James F. HowardJr.Jr.. (2020) Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Frontiers in Neurology 11.
Crossref
Crossref
Kimiaki Utsugisawa, Yuriko Nagane, Akiyuki Uzawa, Hiroyuki Murai, Tomihiro Imai & Shigeaki Suzuki. (2020) Health‐related quality of life and treatment strategies in myasthenia gravis. Clinical and Experimental Neuroimmunology 11:4, pages 209-217.
Crossref
Crossref
Yoshihiko Isshiki, Osamu Mimura & Fumi Gomi. (2020) Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis. Japanese Journal of Ophthalmology 64:6, pages 628-634.
Crossref
Crossref
Liqun Xu, Zhibin Li, Yi Li, Zhaohui Luo, Yuebei Luo, Bo Xiao & Huan Yang. (2020) The Expression Pattern and Regulatory Mechanism of the G0/G1 Switch Gene 2 (G0S2) in the Pathogenesis and Treatment of AChR Myasthenia Gravis (MG). Mediators of Inflammation 2020, pages 1-11.
Crossref
Crossref
Marc Pawlitzki, Uwe K. Zettl, Tobias Ruck, Leoni Rolfes, Hans-Peter Hartung & Sven G. Meuth. (2020) Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-PandemieRisks and possibilities of immunotherapy in times of the coronavirus 2019 pandemic. DGNeurologie 3:4, pages 285-297.
Crossref
Crossref
Mariapaola Marino, Umberto Basile, Gregorio Spagni, Cecilia Napodano, Raffaele Iorio, Francesca Gulli, Laura Todi, Carlo Provenzano, Emanuela Bartoccioni & Amelia Evoli. (2020) Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis. Frontiers in Immunology 11.
Crossref
Crossref
John Morren & Yuebing Li. (2020) Maintenance immunosuppression in myasthenia gravis, an update. Journal of the Neurological Sciences 410, pages 116648.
Crossref
Crossref
Enrique Gomez-Figueroa, Sofía Garcia-Trejo, Lisette Bazan-Rodriguez, Roberto Cervantes-Uribe, German Chac-Lezama, Juan Carlos López-Hernández & Steven Vargas-Cañas. (2019) Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. Journal of Neurology 267:3, pages 674-678.
Crossref
Crossref
Martijn R. Tannemaat & Jan J.G.M. Verschuuren. (2020) Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Neuromuscular Disorders 30:2, pages 111-119.
Crossref
Crossref
Valentina Damato, Stuart Viegas & Angela Vincent. 2020. The Autoimmune Diseases. The Autoimmune Diseases
1011
1033
.
Elizabeth Dansie Bacci, Karin S. Coyne, Jiat-Ling Poon, Linda Harris & Audra N. Boscoe. (2019) Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurology 19:1.
Crossref
Crossref
Kristen Fisher & Veeral Shah. (2019) Pediatric Ocular Myasthenia Gravis. Current Treatment Options in Neurology 21:10.
Crossref
Crossref
Tomihiro Imai. (2019) Why is development of new treatments necessary for myasthenia gravis? Recent advances in clinical trials. Neurology and Clinical Neuroscience 7:4, pages 161-165.
Crossref
Crossref
Amelia Evoli, Giovanni Antonini, Carlo Antozzi, Antonio DiMuzio, Francesco Habetswallner, Cesare Iani, Maurizio Inghilleri, Rocco Liguori, Renato Mantegazza, Roberto Massa, Elena Pegoraro, Roberta Ricciardi & Carmelo Rodolico. (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurological Sciences 40:6, pages 1111-1124.
Crossref
Crossref
Nils Erik Gilhus, Socrates Tzartos, Amelia Evoli, Jacqueline Palace, Ted M. Burns & Jan J. G. M. Verschuuren. (2019) Myasthenia gravis. Nature Reviews Disease Primers 5:1.
Crossref
Crossref
Liang Wang, Xiao Huan, Jian-Ying Xi, Hui Wu, Lei Zhou, Jia-Hong Lu, Tian-Song Zhang & Chong-Bo Zhao. (2019) Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis. CNS Neuroscience & Therapeutics 25:5, pages 647-658.
Crossref
Crossref
Liang Wang, Jianying Xi, Suxian Zhang, Hui Wu, Lei Zhou, Jiahong Lu, Tiansong Zhang & Chongbo Zhao. (2019) Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis. Journal of Clinical Neuroscience 63, pages 160-167.
Crossref
Crossref
Arnold I. Levinson. 2019. Clinical Immunology. Clinical Immunology
879
890.e1
.
Matthew G. Fillingim & Adam J. Woods. 2019. Encyclopedia of Gerontology and Population Aging. Encyclopedia of Gerontology and Population Aging
1
8
.
Ahmad R. Abuzinadah, Duaa JabariOmar JawdatMamatha PasnoorMelanie GlennLaura HerbelinApril L. McVeyRichard J. BarohnMazen M. Dimachkie. (2018) Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis. Journal of Clinical Neuromuscular Disease 20:2, pages 49-59.
Crossref
Crossref
Tomihiro Imai, Kimiaki Utsugisawa, Hiroyuki Murai, Emiko Tsuda, Yuriko Nagane, Yasushi Suzuki, Naoya Minami, Akiyuki Uzawa, Naoki Kawaguchi, Masayuki Masuda, Shingo Konno, Hidekazu Suzuki, Tetsuya Akaishi & Masashi Aoki. (2018) Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. Journal of Neurology, Neurosurgery & Psychiatry 89:5, pages 513-517.
Crossref
Crossref
Zhiguo Li, Minshu Li, Kristofer Wood, Steffan Hettwer, Suraj A. Muley, Fu-Dong Shi, Qiang Liu & Shafeeq S. Ladha. (2018) Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis. Muscle & Nerve 57:5, pages 814-820.
Crossref
Crossref
Karen HewettDonald B. SandersRichard A. GroveChristine L. BroderickTodd J. RudoAshlyn BassiriMarina Zvartau-HindVera BrilLaurence Adams, Sankar Bandyopadhyay, Said Beydoun, Felix Bischof, Mazen Dimachkie, Miriam Freimer, Maurizio Inghilleri, Henry Kaminski, Renato Mantegazza, Tahseen Mozaffar, Michael Nicolle, Khema Sharma, Zaeemi Siddiqi, Ericka Simpson, Florian Then Bergh, Tuan Vu, Radwa Aly, Carlo Antozzi, Richard J. Barohn, Derrick Blackmore, Silvia Bonanno, Angela Campanella, Tiyonnoh Cash, Bakri Elsheikh, Vittorio Frasca, Namita Goyal, Brittany Harvey, Eugene Lai, Lorenzo Maggi, Brian Minton, Veronica Martin, Emanuela Onesti, Mamatha Pasnoor, Gulmohor Roy, Sheetal Shroff & Jason Thonhoff. (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90:16.
Crossref
Crossref
. 2018. Sedation. Sedation
529
559
.
Anna Rostedt Punga, Henry J. Kaminski & Jeffrey T. Guptill. 2018. Myasthenia Gravis and Related Disorders. Myasthenia Gravis and Related Disorders
319
333
.
Jeroen M. H. Hendriks, Patrick Lauwers, Rudy Mercelis, Senne Van Donink, Pieter Mertens & Paul E. Y. Van Schil. 2018. Atlas of Robotic Thoracic Surgery. Atlas of Robotic Thoracic Surgery
83
87
.
Nages Nagaratnam, Kujan Nagaratnam & Gary CheukNages Nagaratnam, Kujan Nagaratnam & Gary Cheuk. 2018. Geriatric Diseases. Geriatric Diseases
351
360
.
Konstantinos Lazaridis, Ioannis Dalianoudis, Vasiliki Baltatzidi & Socrates J. Tzartos. (2017) Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis. Journal of Neuroimmunology 312, pages 24-30.
Crossref
Crossref
Kangmin Kim, Hyun Joo Lee, Samina Park, Yoohwa Hwang, Young Whan Kim & Young Tae Kim. (2017) Successful Lung Transplantation in a Patient with Myasthenia Gravis. The Korean Journal of Thoracic and Cardiovascular Surgery 50:5, pages 382-385.
Crossref
Crossref
Kimiaki Utsugisawa, Yuriko Nagane, Tetsuya Akaishi, Yasushi Suzuki, Tomihiro Imai, Emiko Tsuda, Naoya Minami, Akiyuki Uzawa, Naoki Kawaguchi, Masayuki Masuda, Shingo Konno, Hidekazu Suzuki, Hiroyuki Murai & Masashi Aoki. (2017) Early fast‐acting treatment strategy against generalized myasthenia gravis. Muscle & Nerve 55:6, pages 794-801.
Crossref
Crossref
Ozlem Gungor-Tuncer, Vuslat Yilmaz, Alper Toker, Guher Saruhan-Direskeneli, Yesim Gulsen-Parman, Piraye Oflazer-Serdaroglu & Feza Deymeer. (2017) Prompt Response to Prednisone Predicts Benign Course in MuSK-MG. European Neurology 78:3-4, pages 137-142.
Crossref
Crossref
Yun Jing, Xinxin Liu, Lei Yu & Ran Li. (2017) Outcomes of Preoperative and Postoperative Corticosteroid Therapies in Myasthenia Gravis. European Neurology, pages 73-78.
Crossref
Crossref
Nages Nagaratnam, Kujan Nagaratnam & Gary CheukNages Nagaratnam, Kujan Nagaratnam & Gary Cheuk. 2017. Geriatric Diseases. Geriatric Diseases
1
10
.
Jintana B. Andersen, Nils Erik Gilhus & Donald B. Sanders. (2016) Factors affecting outcome in myasthenia gravis. Muscle & Nerve 54:6, pages 1041-1049.
Crossref
Crossref
P. R. Bourque, C. E. Pringle, W. Cameron, J. Cowan & J. Warman Chardon. (2016) Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study. PLOS ONE 11:8, pages e0159993.
Crossref
Crossref
Masaki Kamada, Shunya Nakane, Naoko Matsui, Osamu Higuchi, Waka Sakai, Koji Fujita, Yuishin Izumi, Hidenori Matsuo & Ryuji Kaji. (2016) Ocular myasthenia gravis with anti‐muscle‐specific tyrosine kinase antibodies: Two new cases and a systematic literature review. Clinical and Experimental Neuroimmunology 7:2, pages 168-173.
Crossref
Crossref
Mathias Mäurer. (2016) Welche Rolle spielt Cyclosporin A bei der Behandlung der Myasthenia gravis?. DNP - Der Neurologe und Psychiater 17:3, pages 34-35.
Crossref
Crossref
Kee Hong ParkJunghee JungJung-Hee LeeYoon-Ho Hong. (2016) Blood Transcriptome Profiling in Myasthenia Gravis Patients to Assess Disease Activity: A Pilot RNA-seq Study. Experimental Neurobiology 25:1, pages 40.
Crossref
Crossref
Inga Koneczny, Pilar Martinez Martinez & Marc De Baets. 2016. Encyclopedia of Immunobiology. Encyclopedia of Immunobiology
168
179
.
Jeffrey T. Guptill, Madhu Soni & Matthew N. Meriggioli. (2015) Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics 13:1, pages 118-131.
Crossref
Crossref
Pei Chen, Huiyu Feng, Juan Deng, Yufei Luo, Li Qiu, Changyi Ou & Weibin Liu. (2015) Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. Journal of Neurology 263:1, pages 83-88.
Crossref
Crossref
M. I. Boldingh, L. Dekker, A. H. Maniaol, C. Brunborg, A. F. Lipka, E. H. Niks, J. J. G. M. Verschuuren & C. M. E. Tallaksen. (2015) An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health and Quality of Life Outcomes 13:1.
Crossref
Crossref
Marinos C. Dalakas. (2015) Future perspectives in target-specific immunotherapies of myasthenia gravis. Therapeutic Advances in Neurological Disorders 8:6, pages 316-327.
Crossref
Crossref
Linda L. Kusner & Henry J. Kaminski. (2015) Editorial: Special issue on standardization of preclinical evaluation of animal models for myasthenia gravis. Experimental Neurology 270, pages 1-2.
Crossref
Crossref
A. Ramos‐Fransi, R. Rojas‐García, S. Segovia, C. Márquez‐Infante, J. Pardo, J. Coll‐Cantí, I. Jericó & I. Illa. (2015) Myasthenia gravis: descriptive analysis of life‐threatening events in a recent nationwide registry. European Journal of Neurology 22:7, pages 1056-1061.
Crossref
Crossref
Tomihiro Imai, Shigeaki Suzuki, Emiko Tsuda, Yuriko Nagane, Hiroyuki Murai, Masayuki Masuda, Shingo Konno, Yasushi Suzuki, Shunya Nakane, Kazuo Fujihara, Norihiro Suzuki & Kimiaki Utsugisawa. (2015) Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle & Nerve 51:5, pages 692-696.
Crossref
Crossref
Henrik Berg Rasmussen, Ditte Bjerre, Kristian Linnet, Gesche Jürgens, Kim Dalhoff, Hreinn Stefansson, Thomas Hankemeier, Rima Kaddurah-Daouk, Olivier Taboureau, Søren Brunak, Tine Houmann, Pia Jeppesen, Anne Katrine Pagsberg, Kerstin Plessen, Jørgen Dyrborg, Peter Riis Hansen, Poul Erik Hansen, Tim Hughes & Thomas Werge. (2015) Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics 16:6, pages 649-665.
Crossref
Crossref
Jennifer L. Cruz, Marissa L. Wolff, Adam J. Vanderman & Jamie N. Brown. (2015) The emerging role of tacrolimus in myasthenia gravis. Therapeutic Advances in Neurological Disorders 8:2, pages 92-103.
Crossref
Crossref
Hiroyuki Murai. (2015)
J
apanese clinical guidelines for myasthenia gravis: Putting into practice
. Clinical and Experimental Neuroimmunology 6:1, pages 21-31.
Crossref
Crossref
Virginia Chun‐Nei Wong. (2014)
My 30‐year roadmap for pediatric myasthenia gravis in
H
ong
K
ong: Searching for international collaboration
. Clinical and Experimental Neuroimmunology 6:1, pages 13-20.
Crossref
Crossref
Ritesh Kumar. (2015) Myasthenia gravis and thymic neoplasms: A brief review. World Journal of Clinical Cases 3:12, pages 980.
Crossref
Crossref
K. Lazaridis, P. Evaggelakou, E. Bentenidi, A. Sideri, E. Grapsa & S.J. Tzartos. (2015) Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains. Journal of Neuroimmunology 278, pages 19-25.
Crossref
Crossref
Donald B. Sanders & Jeffrey T. Guptill. (2014) Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome. CONTINUUM: Lifelong Learning in Neurology 20, pages 1413-1425.
Crossref
Crossref
Kimiaki Utsugisawa, Shigeaki Suzuki, Yuriko Nagane, Masayuki Masuda, Hiroyuki Murai, Tomihiro Imai, Emiko Tsuda, Shingo Konno, Shunya Nakane, Yasushi Suzuki, Kazuo Fujihara & Norihiro Suzuki. (2014) Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle & Nerve 50:4, pages 493-500.
Crossref
Crossref
Manjistha Sengupta, Amrita Cheema, Henry J. Kaminski & Linda L. Kusner. (2014) Serum Metabolomic Response of Myasthenia Gravis Patients to Chronic Prednisone Treatment. PLoS ONE 9:7, pages e102635.
Crossref
Crossref
Linda L. Kusner, Namita Satija, Georgiana Cheng & Henry J. Kaminski. (2014) Targeting therapy to the neuromuscular junction: Proof of concept. Muscle & Nerve 49:5, pages 749-756.
Crossref
Crossref
Khalid El-Salem, Ahmed Yassin, Kefah Al-Hayk, Salma Yahya, Duha Al-Shorafat & Said S. Dahbour. (2014) Treatment of MuSK-Associated Myasthenia Gravis. Current Treatment Options in Neurology 16:4.
Crossref
Crossref
Marinos C. Dalakas. (2014) IVIg in the chronic management of myasthenia gravis: Is it enough for your money?. Journal of the Neurological Sciences 338:1-2, pages 1-2.
Crossref
Crossref
Manuel Serrano, Jose Angel Martínez-Flores, Maria José Castro, Florencio García, David Lora, Dolores Pérez, Esther Gonzalez, Estela Paz-Artal, Jose M. Morales & Antonio Serrano. (2014) Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease. Journal of Immunology Research 2014, pages 1-10.
Crossref
Crossref
Stuart Viegas & Angela Vincent. 2014. The Autoimmune Diseases. The Autoimmune Diseases
777
791
.
Yoshito Yamada, Shigetoshi Yoshida, Hidemi Suzuki, Tetsuzo Tagawa, Takekazu Iwata, Teruaki Mizobuchi, Naoki Kawaguchi & Ichiro Yoshino. (2013) Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients. Journal of Cardiothoracic Surgery 8:1.
Crossref
Crossref
Syuichi Tetsuka, Ken-ichi Fujimoto & Kunihiko Ikeguchi. (2013) Preoperative High-Dose Steroid Has Long-Term Beneficial Effects for Myasthenia Gravis. Neurology Research International 2013, pages 1-7.
Crossref
Crossref
Marinos C. Dalakas. (2013) Novel future therapeutic options in Myasthenia Gravis. Autoimmunity Reviews 12:9, pages 936-941.
Crossref
Crossref
Amelia Evoli & Luca Padua. (2013) Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmunity Reviews 12:9, pages 931-935.
Crossref
Crossref
Cristian M. Ionita & Gyula Acsadi. (2013) Management of Juvenile Myasthenia Gravis. Pediatric Neurology 48:2, pages 95-104.
Crossref
Crossref
Shunya Nakane. (2013) Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis. Rinsho Shinkeigaku 53:11, pages 1309-1311.
Crossref
Crossref
Yuriko Nagane. (2013) Clinical factors affecting quality of life and treatment targets in patients with myasthenia gravis. Rinsho Shinkeigaku 53:11, pages 1299-1302.
Crossref
Crossref
Kane O. Pryor & Kingsley P. Storer. 2013. Pharmacology and Physiology for Anesthesia. Pharmacology and Physiology for Anesthesia
180
207
.
Arnold I. Levinson. 2013. Clinical Immunology. Clinical Immunology
782
792
.
Mohammad Reza Lashkarizadeh, Rasoul Ajami, Mehrdad Vahedian, Bahram Pourseyedi, Hamid Zeynali, Mitra Samareh Fekri & Massoud Baghai Wadji. (2012) Video-Assisted Thoracoscopic Thymectomy as an Optimal Treatment in Myasthenia Gravis. Journal of Minimally Invasive Surgical Sciences 1:4, pages 144-148.
Crossref
Crossref
Marinos C. Dalakas. (2012) Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. Annals of the New York Academy of Sciences 1274:1, pages 1-8.
Crossref
Crossref
Alejandro M. Gomez, Nick Willcox, Peter C. Molenaar, Wim Buurman, Pilar Martinez-Martinez, Marc H. De Baets & Mario Losen. (2012) Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?. Annals of the New York Academy of Sciences 1274:1, pages 48-59.
Crossref
Crossref
Konstantinos Lazaridis, Paraskevi Zisimopoulou, George Lagoumintzis, Labrini Skriapa, Nikos Trakas, Panagiota Evangelakou, Ioannis Kanelopoulos, Eirini Grapsa, Kostas Poulas & Socrates Tzartos. (2012) Antigen-specific apheresis of autoantibodies in myasthenia gravis. Annals of the New York Academy of Sciences 1275:1, pages 7-12.
Crossref
Crossref
Amelia Evoli, Paolo E. Alboini, Ana Bisonni, Alessia Mastrorosa & Emanuela Bartocccioni. (2012) Management challenges in muscle-specific tyrosine kinase myasthenia gravis. Annals of the New York Academy of Sciences 1274:1, pages 86-91.
Crossref
Crossref
Fulvio Baggi, Carlo Antozzi, Chiara Toscani & Chiara Cordiglieri. (2011) Acetylcholine Receptor-Induced Experimental Myasthenia Gravis: What Have We Learned from Animal Models After Three Decades?. Archivum Immunologiae et Therapiae Experimentalis 60:1, pages 19-30.
Crossref
Crossref
Kimiaki Utsugisawa, Yuriko Nagane, Shigeaki Suzuki & Norihiro Suzuki. (2012) Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis: therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids. Rinsho Shinkeigaku 52:11, pages 1047-1050.
Crossref
Crossref
Matthew N. Meriggioli & Donald B. Sanders. 2012. Neurology in Clinical Practice. Neurology in Clinical Practice
2046
2065
.
P. J. Chien, J. H. Yeh, H. C. Chiu, Y. M. Hsueh, C. T. Chen, M. C. Chen & C. M. Shih. (2011) Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis. European Journal of Neurology 18:11, pages 1350-1357.
Crossref
Crossref
Paola Cavalcante, Rozen Le Panse, Sonia Berrih‐aknin, Lorenzo Maggi, Carlo Antozzi, Fulvio Baggi, Pia Bernasconi & Renato Mantegazza. (2011) The thymus in myasthenia gravis: Site of “innate autoimmunity”?. Muscle & Nerve 44:4, pages 467-484.
Crossref
Crossref
Alejandro M. Gomez, Kathleen Vrolix, Pilar Martínez-Martínez, Peter C. Molenaar, Marko Phernambucq, Eline van der Esch, Hans Duimel, Fons Verheyen, Reinhard E. Voll, Rudolf A. Manz, Marc H. De Baets & Mario Losen. (2011) Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis. The Journal of Immunology 186:4, pages 2503-2513.
Crossref
Crossref
Jozsef Pal, Csilla Rozsa, Samuel Komoly & Zsolt Illes. (2011) Clinical and biological heterogeneity of autoimmune myasthenia gravis. Journal of Neuroimmunology 231:1-2, pages 43-54.
Crossref
Crossref
Nils Erik Gilhus, Jone F. Owe, Jana Midelfart Hoff, Fredrik Romi, Geir Olve Skeie & Johan A. Aarli. (2011) Myasthenia Gravis: A Review of Available Treatment Approaches. Autoimmune Diseases 2011, pages 1-6.
Crossref
Crossref
Fredrik Romi. (2011) Thymoma in Myasthenia Gravis: From Diagnosis to Treatment. Autoimmune Diseases 2011, pages 1-5.
Crossref
Crossref
Jee Young KimKee Duk ParkDavid P. Richman. (2011) Treatment of Myasthenia Gravis Based on Its Immunopathogenesis. Journal of Clinical Neurology 7:4, pages 173.
Crossref
Crossref
Lisa Knopf & Daniel L Menkes. (2010) Comorbid HIV and Myasthenia Gravis: Case Report and Review of the Literature. Journal of Clinical Neuromuscular Disease 12:2, pages 80-84.
Crossref
Crossref